HUTCHMED (HCM) vests 726,317 LTIP shares to CEO and CFO

Rhea-AI Filing Summary

HUTCHMED (China) Limited reported that long-term incentive awards granted on June 5, 2023 under its Long Term Incentive Plan have vested following the announcement of its 2025 annual results. On March 10, 2026, 524,079 ordinary shares vested to Dr Weiguo Su and 202,238 ordinary shares vested to Mr Johnny Cheng, totaling 726,317 shares.

These awards vested at nil price and relate to ordinary shares of US$0.10 each. Both executives are classified as persons discharging managerial responsibilities, and the transactions took place outside a trading venue, in line with UK Market Abuse Regulation notification requirements.

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​

​

FORM 6-K

​

​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of March 2026

​

Commission File Number: 001-37710

​

​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​

​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​

​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​

​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.	​ ​ ​	Description
​	​	​
Exhibit 99.1	​	Announcement relating to vesting of awards under the long term incentive plan
​	​	​
​	​	​
​	​	​

2

​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​	HUTCHMED (CHINA) LIMITED
​	​	​
​	​	​
​	By:	/s/ Johnny Cheng
​	Name:	Johnny Cheng
​	Title:	Chief Financial Officer

​

​

Date: March 11, 2026

3

​

Exhibit 99.1

​

​

Vesting of awards under the Long Term Incentive Plan

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 11, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; SEHK:13) announces that following the announcement of the 2025 annual results of HUTCHMED on March 5, 2026, the following awards granted under the Long Term Incentive Plan (“LTIP”) on June 5, 2023 to Dr Weiguo Su and Mr Johnny Cheng were vested on March 10, 2026:-

​

	​
Award Holders	​	Number of ordinary shares
Person Discharging Managerial Responsibilities
Dr Weiguo Su (Executive Director, Chief Executive Officer and Chief Scientific Officer)	​	524,079
Mr Johnny Cheng (Executive Director, Acting Chief Executive Officer and Chief Financial Officer)	​	202,238
Total	​	726,317

​

The notifications set out below are provided in accordance with the requirements of the UK Market Abuse Regulation.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(a) Dr Weiguo Su

​

​

​ ​	​ ​	​ ​
1	Details of the person discharging managerial responsibilities/person closely associated
​ a)	​ Name	​ Dr Weiguo Su
2	Reason for the notification
​ a)	​ Position/status	​ Executive Director, Chief Executive Officer and Chief Scientific Officer
​ b)	​ Initial notification/Amendment	​ Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
​ a)	​ Name	​ HUTCHMED (China) Limited
​ b)	​ LEI	​ 2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
​ a)	​ Description of the financial instrument, type of instrument ​ Identification code	​ Ordinary Shares of US$0.10 ​ ​ Ordinary Share with DI ISIN: KYG4672N1016
​ b)	​ Nature of the transaction	​ Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP
​ c)	​ Price(s) and volume(s)	​	​	​	​
		​	​	​	Price(s)	Volume(s)	​
		​	​	​	Nil	524,079 ordinary shares	​
		​	​	​	​	​	​
​ d)	​ Aggregated information — Aggregated volume — Price​	​ N/A
​ e)	​ Date of the transaction	​ 2026-03-10
​ f)	​ Place of the transaction	​ Outside a trading venue

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

​

(b) Mr Johnny Cheng

​

​

​ ​	​ ​	​ ​
1	Details of the person discharging managerial responsibilities/person closely associated
​ a)	​ Name	​ Mr Johnny Cheng
2	Reason for the notification
​ a)	​ Position/status	​ Executive Director, Acting Chief Executive Officer and Chief Financial Officer
​ b)	​ Initial notification/Amendment	​ Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
​ a)	​ Name	​ HUTCHMED (China) Limited
​ b)	​ LEI	​ 2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
​ a)	​ Description of the financial instrument, type of instrument ​ Identification code	​ Ordinary Shares of US$0.10 ​ ​ Ordinary Share with DI ISIN: KYG4672N1016
​ b)	​ Nature of the transaction	​ Vesting of awards granted on June 5, 2023 under HUTCHMED's LTIP
​ c)	​ Price(s) and volume(s)	​	​	​	​
		​	​	​	Price(s)	Volume(s)	​
		​	​	​	Nil	202,238 ordinary shares	​
		​	​	​	​	​	​
​ d)	​ Aggregated information — Aggregated volume ​ ​ — Price ​	​ N/A
​ e)	​ Date of the transaction	​ 2026-03-10
​ f)	​ Place of the transaction	​ Outside a trading venue

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

​

​

CONTACTS

Investor Enquiries	+852 2121 8200 / ir@hutch-med.com
	​
Media Enquiries	​
FTI Consulting –	+44 20 3727 1030 / HUTCHMED@fticonsulting.com
Ben Atwell / Tim Stamper	+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)
Brunswick – Zhou Yi	+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com
	​
Panmure Liberum	Nominated Advisor and Joint Broker
Atholl Tweedie / Emma Earl / Rupert Dearden	+44 20 7886 2500
	​
Cavendish	Joint Broker
Geoff Nash / Nigel Birks	+44 20 7220 0500
	​
Deutsche Numis	Joint Broker
Freddie Barnfield / Jeffrey Wong / Duncan Monteith	+44 20 7260 1000

​

FAQ

What did HUTCHMED (HCM) announce in this Form 6-K filing?

HUTCHMED announced the vesting of long-term incentive plan awards granted on June 5, 2023. On March 10, 2026, share awards to two senior executives vested following the company’s 2025 annual results, with detailed volumes disclosed for regulatory transparency.

How many HUTCHMED shares vested to Dr Weiguo Su under the LTIP?

Dr Weiguo Su had 524,079 ordinary shares vest under HUTCHMED’s Long Term Incentive Plan. These awards were granted on June 5, 2023 and vested on March 10, 2026 at nil price, following the announcement of the company’s 2025 annual results.

How many HUTCHMED shares vested to CFO Johnny Cheng?

Johnny Cheng had 202,238 ordinary shares vest under the Long Term Incentive Plan. The awards were originally granted on June 5, 2023 and vested on March 10, 2026 at nil price, reflecting part of his executive compensation as disclosed for regulatory purposes.

What is the total number of HUTCHMED LTIP shares that vested in March 2026?

A total of 726,317 ordinary shares vested under HUTCHMED’s Long Term Incentive Plan. This total consists of 524,079 shares for Dr Weiguo Su and 202,238 shares for Johnny Cheng, with vesting effective on March 10, 2026 after the 2025 results announcement.

At what price did the HUTCHMED LTIP awards vest for the executives?

The vested LTIP awards for both executives carried a price of nil. This means the ordinary shares of US$0.10 par value were delivered without a purchase price on vesting, consistent with standard share-based compensation structures disclosed in the notification.

Where were the HUTCHMED LTIP transactions for Su and Cheng executed?

The LTIP vesting transactions for both Dr Weiguo Su and Johnny Cheng were recorded as occurring outside a trading venue. This reflects that the awards were share-based compensation events rather than open-market trades, as required to be disclosed under UK Market Abuse Regulation.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 87.5 KB